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This data in brief describes characteristics of chronic stable
comorbid patients who were included in reference range studies of
[IGFBP7]  [TIMP-2] “Reference Intervals of Urinary Acute Kidney
Injury (AKI) Markers [IGFBP7]  [TIMP2] in Apparently Healthy
Subjects and Chronic Comorbid Subjects without AKI” [1]. In order
to determine the specificity of [IGFBP7]  [TIMP-2] for identifying
patients at risk of developing AKI we studied a cohort with nine
broad classification of disease who did not have AKI. Details
regarding the population that was targeted for inclusion in the
study are also described. Finally, we present data on the inclusion
criteria for the healthy subjects used in this investigation to
determine the reference range.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.cca.2015.10.029
erald).
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ject areaAcute kidney injuryype of data Tables
ow data was
acquiredList of patient characteristicsata format Tables
xperimental
factorsHealthy subjects and chronic comorbid subjects without acute kidney injuryxperimental
featuresDesign of experiments reflect US patient characteristicsata source
locationSubjects recruited from Rochester, NY; Dallas, TX; Gresham, OR; Springfield, MO;
Layton, UT; Peoria, AZata accessibility Data are with this articleDValue of the data The data described allow other researchers to understand the patient cohort we used to determine
the specificity of the AKI biomarkers [IGFBP7]  [TIMP-2] in the setting of stable chronic comorbid
conditions.
 We included patients with cardiovascular, respiratory, gastrointestinal, renal, muscular skeletal,
endocrine, and neuromuscular disease in the stable chronic comorbid condition cohort who did
not have AKI, which serves as a model for future studies.
 We describe inclusion criteria for a healthy reference range population that can also be used for
future studies evaluating biomarkers of AKI.1. Data
The data described provide details on the conditions and numbers of subjects evaluated who did
not have AKI but did have other chronic stable comorbid conditions that were used to demonstrate
the specificity of these biomarkers for AKI. We also describe the targeted patient population and the
inclusion criteria that were used to determine the reference range of [IGFBP7]  [TIMP-2] in healthy
individuals.2. Experimental design, materials and methods
The reference range study was designed to include patients commonly seen in intensive care units
of hospitals in the United States [2]. The list of patients with chronic stable comorbid conditions is
presented in Table 1. Table 2 gives a description of patient demographics that were targeted for
inclusion. Table 3 provides detailed inclusion criteria used to select the healthy reference range
population.
The protocols for this investigation were approved by investigational review boards/ethics com-
mittees as required by each participating institution. All subjects provided written informed consent.
Subjects of Z21 years age, who provided written informed consent for the study participation, and
met the morbidity criteria (Table 1) were selected in the stable chronic morbidity cohort. For
Table 1
Medical conditions for chronic stable morbidity cohort (N¼372).
Medical condition N %
Any cardiovascular 237 (63.7)
CAD 27 (7.3)
Bypass graft 2 (0.5)
CHF 12 (3.2)
Hypertension 222 (59.7)
MI 0 (0.0)
Arrhythmia 32 (8.6)
PVD 5 (1.3)
Any respiratory 99 (26.6)
Emphysema 10 (2.7)
Sleep apnea 41 (11.0)
COPD 32 (8.6)
Chronic bronchitis 16 (4.3)
Asthma 51 (13.7)
Any gastrointestinal 14 (3.8)
Cirrhosis 2 (0.5)
Hepatic failure 0 (0.0)
IBD 5 (1.3)
Peptic ulcers 1 (0.3)
Chronic pancreatitis 0 (0.0)
GI bleeding 1 (0.3)
Crohn's disease 1 (0.3)
Ulcerative colitis 4 (1.1)
Any renal 13 (3.5)
Renal insufficiency 6 (1.6)
Polycystic kidney disease 1 (0.3)
Nephrolithiasis 4 (1.1)
Other 6 (1.6)
Any musculoskeletal 116 (31.2)
Osteoarthritis 107 (28.8)
Gout 15 (4.0)
Any endocrine/metabolic 255 (68.5)
Any Diabetes 91 (24.5)
Type I Diabetes 7 (1.9)
Type II Diabetes 84 (22.6)
Hypercholesterolemia 149 (40.1)
Hyperlipidemia 53 (14.2)
Hyperthyroidism 6 (1.6)
Hypothyroidism 69 (18.5)
Metabolic syndrome 1 (0.3)
Any neurological 41 (11.0)
Neuromuscular disease 19 (5.1)
Stroke 0 (0.0)
Seizures 3 (0.8)
Migraines 25 (6.7)
Any immune disorder 21 (5.6)
Rheumatoid arthritis 16 (4.3)
Immunocompromised 4 (1.1)
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Table 2
The following percent distribution for age, race, ethnicity and gender was targeted during
selection of participants. This distribution was targeted to reflect the general demographic data
for United States intensive care units.
Percentage of total enrollment (%)
Age range (years)
o46 12
46-55 16
56–65 20
66–75 26
475 26
Race
Black 14
White 72
American Indian/Alaskan 1
Other 13
Ethnicity
Hispanic/Latino 9
Not Hispanic Latino 91
Gender
Female 50
Male 50
Table 1 (continued )
Medical condition N %
Lupus 2 (0.5)
AIDS 0 (0.0)
Other conditions 214 (57.5)
Coagulation abnormality 4 (1.1)
Organ transplant 0 (0.0)
Trauma 0 (0.0)
Surgeries 0 (0.0)
BPH 38 (21.0)
Psoriasis 8 (2.2)
Drug Abuse 5 (1.3)
Any Other 189 (50.8)
Cancer 9 (2.4)
Any metastatic cancer 1 (0.3)
Active cancer 5 (1.3)
Cured/In remission 3 (0.8)
CAD, coronary artery disease; CHF, congestive heart failure; MI,
myocardial infarction; PVD, peripheral vascular disease; COPD,
chronic obstructive pulmonary disease; IBD, inflammatory bowel
disease; GI, gastrointestinal; AIDS, acquired immunodeficiency
syndrome; and BPH, benign prostatic hypertrophy.
N.S. Chindarkar et al. / Data in Brief 5 (2015) 888–892 891apparently healthy subjects, individuals of Z21 years of age, who provided written informed consent
for study participation, and met the healthy criteria (Table 2), were selected for this cohort.
The patients were recruited at 6 geographically diverse sites (Rochester, NY; Dallas, TX; Gresham,
OR; Springfield, MO; Layton, UT; Peoria, AZ). In the stable chronic comorbid cohort most patients had
several comorbidities, with the most prevalent being some type of an endocrine or cardiovascular
Table 3
List of apparently healthy subject criteria.
A subject was deemed apparently healthy, if he or she was Z21 years of age, did not have any chronic, stable morbid
conditions (see Table 1), and met all following criteria:
1. Subject without any known or suspected acute illness or condition-including acute infections – at the time of
enrollment or within the previous 30 days
2. Subject without any new onset or unstable morbidities listed under “Chronic, stable morbid conditions”
3. Subject without any trauma-related surgery within the last 6 months
4. Subject without any surgery, hospitalization or institutionalization (such as in a nursing home) during the previous
3 months
5. Subject did not receive any blood product transfusion within the previous 2 months
6. Subject who was not a pregnant woman or child
7. Subject was not prisoners or institutionalized individual
8. Subject who did not provide evaluable blood or urine samples for this study
N.S. Chindarkar et al. / Data in Brief 5 (2015) 888–892892disorder. In terms of specific comorbidities, as might be expected for the US population, the highest
prevalence was hypertension (59.7%) with the other top four being hypercholesterolemia (40.1%),
osteoarthritis (28.8%), and diabetes (24.5%).Acknowledgments
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